All News

journal book learning study meeting notes

Excited About ACR Convergence 2020

d Antoni Chan, MD, PhD

I always think of why I attend the ACR: to gain new information and knowledge and bring it back to my clinic for my patients. Here's what I'm looking forward to this year.

Read Article
covid19.logo_.jpg

Six Things Rheumatologists Need to Know About COVID-19

d Rachel Tate, DO

From flu shots and face masks to vaccines and searching for the immunological endotype, here are six things rheumatologists need to know about COVID-19.

Read Article
ACRmtg.jpg (keep)

Industry Abstract Previews - ACR2020

d Jack Cush, MD

Each pharmaceutical company has spent months and years preparing to present and highlight their featured clinical trials and abstracts at ACR 2020.  This is our selection of their best studies for you to review and evaluate as part of your to-do list.

Read Article
Association of Hydroxychloroquine Use with Development of Non-Alcoholic Fatty Liver Disease in Rheumatoid Arthritis https://t.co/3PrWlIGnB8 #RA #HCO #NASH - HCO decreases fatty liver

Links:

Peter Nash drpnash ( View Tweet)

Lymphomas Complicating Rheumatoid Arthritis: Results of a French Multi-Centre Case-Control Study https://t.co/NDk0LH5Kk6 #RA #lymphoma risk driven by increased disease activity

Links:

Peter Nash drpnash ( View Tweet)

Safety Profile of Baricitinib for the Treatment of Rheumatoid Arthritis up to 8.4 Years: An Updated Integrated Safety Analysis https://t.co/i456zSn6Ba #RA #Baricitinib #safety 13000 pt/yrs 8.4 yrs F/U no new safety signals VTE 0.5/100 pt yrs

Links:

Peter Nash drpnash ( View Tweet)

COVID-19 use of dexamethasone- why does it work? When to use it ?Is it hyperferrintemic sepsis? Vs early MAS vs? More data needed but this why rheumatologists are needed!!! @RheumNow #ACR20 thank you dr. Rubin! https://t.co/MvQJGqsqu2
alexa meara lexmeara ( View Tweet)
What is your top concern about the SARS-Co-V2 vaccine for rheum patients? @RheumNow #ACR20

k dao KDAO2011 ( View Tweet)

@JYazdanyMD @UWRheum @r_burmester Black, et al - cont'd 277 atypical femur fx events Risk increased w longer duration of bisphosphonate use Risk decreased after bisphosphonate discontinuation Asians had a higher risk than Whites. #ACR20 #ACRambassador

Rheum Cat rheum_cat ( View Tweet)

New drug mechanisms for SpA. Nice to have expanding options #ACR20 https://t.co/vlTwaiuuS3
Dr Irwin Lim _connectedcare ( View Tweet)
4.CIRT: low dose MTX 15 mg/week: transaminitis NNH 6, cirrhosis NNH 1000 5.LoDoCo2: colchicine prevents MACE: NNT 36 6.ENTRACTE: TCZ vs ETN: for bowel perforation TCZ: NNH 600

k dao KDAO2011 ( View Tweet)

Year in Review by @JYazdanyMD: #Cardiovascular #Inflammation Reduction Trial provided "unique opportunity to learn about side-effects" of a drug we commonly use. Low-dose MTX assoc. with small-mod. elevated risk of transaminitis, infection, anaemia & skin cancer. #ACR20 @RheumNow https://t.co/hNS600Pndr
Mrinalini Dey DrMiniDey ( View Tweet)
How do you monitor HCQ on patients with chronic QTc prolonging medications (ex psychiatric meds)? @JYazdanyMD Year-in-Review #ACR20 @rheumnow

Eric Dein ejdein1 ( View Tweet)

Do you plan to do a skin exam in your RA patients on MTX given new toxicity signal of skin cancer based on CIRT with NNH of 167? @JYazdanyMD #ACR20 Year in Review @RheumNow

Meral K. El Ramahi, MD MeralElRamahiMD ( View Tweet)

Dr Kevin Wei's study with @ilyakorsunsky @Deepakarao @soumya_boston, Dr. Michael Brenner and others at @BrighamResearch featured in the basic year-in-review at #ACR20 showing Notch signaling importance in synovium from arthritis #ACRambassador

Jeff Sparks jeffsparks ( View Tweet)

What is most important clinical study in last year? #ACR20 @rheumnow

Richard Conway RichardPAConway ( View Tweet)

Mavrilimumab (anti GM-CSF Receptor α Monoclonal Antibody) Reduces Time to Flare and Increases Sustained Remission in a Phase 2 Trial of Patients with Giant Cell Arteritis https://t.co/1kqWeBcEDq #gca #GmCSFinh Novel MOA , big unmet need

Links:

Peter Nash drpnash ( View Tweet)

Efficacy & Safety Deucravacitinib (BMS-986165), Oral, Selective TyK2 Inhib in Patients with Active PsA Results from a Phase 2, RDBPC Trial https://t.co/s3V5NtRpuW results-from-a-phase-2-randomized-double-blind-plac/ #psa #tyk2inhib Efficacy in PsA ?top of dose response

Links:

Peter Nash drpnash ( View Tweet)

Long Term Cardiovascular Safety of Febuxostat and Allopurinol in Patients with Chronic Gout: The Febuxostat versus Allopurinol Streamlined Trial (on Behalf of the FAST Investigators) https://t.co/LGERY3mpe5 #febuxostat #allopurinol #CVS some cardiac reassurance feboxustat

Links:

Peter Nash drpnash ( View Tweet)

Tofacitinib for the Treatment of Adult Patients with Ankylosing Spondylitis: Primary Analysis of a Phase 3, Randomized, Double-blind, Placebo-controlled Study https://t.co/F86K1Lqou7 #tofacitinib #AS Tofa works in AS , zoster no VTE seen NNH 20(per SAE) NNT 2.5(per ASAS40)

Links:

Peter Nash drpnash ( View Tweet)

How well do you know this week's rheumatology news?
Take the rheumIQ quiz
Take the RheumIQ Quiz

×